Preventing Adverse Patient Responses to Cancer Chemotherapeutics
Technical Report,01 Jun 2019,31 May 2020
Albert Einstein College of Medicine Bronx United States
Pagination or Media Count:
The purpose of this project is to prevent adverse patient responses to the cancer drug irinotecan by analyzing the gut microbiomes of patients. The scope of this project is to study irinotecan metabolism and the microbiome over time using fecal samples from healthy individuals and metastatic colorectal cancer patients. We have several major findings from the past year of work. We are happy to report a number of significant results for this year. We have successfully collected longitudinal samples for four colorectal cancer patients. We were invited to write a review for Annual Reviews in Pharmacology and Toxicology about microbiome contributions to adverse events and we discuss the potential for microbiome interventions to improve drug and treatment safety and efficacy in colorectal cancer Khan, Hauptman, and Kelly, Ann Rev Pharm Tox, in press. We wrote commentaries on harnessing the microbiome to improve drug therapy Kelly, Clin Pharmacol Ther, 2019 and on microbial metabolism of L-dopa Hitchings and Kelly, Cell Metab, 2019. We developed a novel computational approach to identify metastable states and state transitions in microbiome data that are linked to patient outcomes Chang, VanInsberghe, and Kelly, npj Biofilms and Microbiomes, provisionally accepted. To better predict the likelihood of a patient suffering an adverse event based solely on his or her microbiome, we developed, tested, and validated three machine learning approaches to predict clinical outcomes based on microbiome data Khan and Kelly, Pac Symp Biocomput, 2020. Each publication acknowledges the DoD.
- Medicine and Medical Research